Results 81 to 90 of about 5,304 (170)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice

open access: yesFrontiers in Immunology, 2019
Sepsis is one of the most prevalent diseases in the world. The development of cardiac dysfunction in sepsis results in an increase of mortality. It is known that Bruton's tyrosine kinase (BTK) plays a role in toll-like receptor signaling and NLRP3 ...
Caroline E. O'Riordan   +14 more
doaj   +1 more source

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs

open access: yesJournal of Comparative Effectiveness Research
Aim: Bruton’s tyrosine kinase inhibitors (BTKis), including ibrutinib and acalabrutinib, transformed the treatment landscape of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) by improving outcomes compared with ...
Lindsey Fitzgerald   +9 more
doaj   +1 more source

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas

open access: yesOncology and Therapy
Introduction Bruton tyrosine kinase inhibitor (BTKi) monotherapies have improved patient outcomes in B cell lymphomas; however, evidence on their comparative efficacy remains limited.
Pier Luigi Zinzani   +9 more
doaj   +1 more source

Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia

open access: yesJournal of Comparative Effectiveness Research
Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) from a Medicare perspective.
Adam S Kittai   +6 more
doaj   +1 more source

Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial

open access: yeshealthbook TIMES. Oncology Hematology
Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that predominantly affects older adults and presents significant treatment challenges due to its clinical complexity and poor prognosis.
Adrian Schmidt
doaj   +1 more source

Supplemental Table from The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

open access: yes, 2017
Supplementary Table S1. Kinase selectivity of acalabrutinib as assessed by DiscoveRX KinomeScan screening.
Carsten U. Niemann (14998799)   +19 more
core   +1 more source

Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate [PDF]

open access: yes
Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate Acalabrutinib or 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1- yl}-N-(pyridin-2-yl)benzamide is the active pharmaceutical ingredient (API) in the ...
Anonymous,
core   +1 more source

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis

open access: yesExperimental Hematology & Oncology
Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF); however, the comparative risk of AF between these 2 BTK inhibitors remains largely unknown.
Joachim Alexandre   +11 more
doaj   +1 more source

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials [PDF]

open access: yes
: Before targeted therapies, patients with higher-risk chronic lymphocytic leukemia (CLL) defined as del(17p) and/or TP53 mutation (TP53m), unmutated immunoglobulin heavy chain variable region genes (uIGHV), or complex karyotype (CK) had poorer prognosis
Siddiqi, Tanya   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy